Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1978 Jun;75(6):2955–2958. doi: 10.1073/pnas.75.6.2955

Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes.

L Kaplan, J Weiss, P Elsbach
PMCID: PMC392685  PMID: 275865

Abstract

Inhibition of prostaglandin synthesis by indomethacin, a drug with anti-inflammatory properties, has been attributed to its action on fatty acid cyclooxygenase. However, prostaglandin synthesis would also be inhibited if precursor fatty acids were not supplied. We find that indomethacin inhibits phospholipase A2 (phosphatide 2-acylhydrolase, EC 3.1.1.4) of rabbit polymorphonuclear leukocytes in dose-dependent fashion. Inhibition is immediate and readily detected at 1 micrometer. The extent of inhibition is the same over a 10-fold range of substrate concentration and over a 500-fold range of enzyme purification. Inhibition is of the noncompetitive type, with an apparent Ki of 12 micrometer. Four other phospholipases A2--from venoms of Russell viper, Crotalus adamanteus, and bee, and from pig pancreas--are unaffected by 50 micrometer indomethacin, which inhibits leukocyte phospholipase A2 by 70%. This inhibition at low concentrations may well be important in the effects of the drug on protaglandin synthesis and inflammatory responses.

Full text

PDF
2955

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  2. Bekemeier H., Giessler A. J., Hirschelmann R. Prostaglandins and inflammation. Pol J Pharmacol Pharm. 1974 Jan-Apr;26(1):5–23. [PubMed] [Google Scholar]
  3. Borgeat P., Hamberg M., Samuelsson B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem. 1976 Dec 25;251(24):7816–7820. [PubMed] [Google Scholar]
  4. ELBACH P. Composition and synthesis of lipids in resting and phagocytizing leukocytes. J Exp Med. 1959 Dec 1;110:969–980. doi: 10.1084/jem.110.6.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elsbach P., Farrow S. Cellular triglyceride as a source of fatty acid for lecithin synthesis during phagocytosis. Biochim Biophys Acta. 1969 Mar 4;176(2):438–441. doi: 10.1016/0005-2760(69)90208-2. [DOI] [PubMed] [Google Scholar]
  6. Elsbach P. Lipid metabolism by phagocytes. Semin Hematol. 1972 Jul;9(3):227–239. [PubMed] [Google Scholar]
  7. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  8. Franson R., Patriarca P., Elsbach P. Phospholipid metabolism by phagocytic cells. Phospholipases A2 associated with rabbit polymorphonuclear leukocyte granules. J Lipid Res. 1974 Jul;15(4):380–388. [PubMed] [Google Scholar]
  9. Higgs G. A., McCall E., Youlten L. J. A chemotactic role for prostaglandins released from polymorphonuclear leucocytes during phagocytosis. Br J Pharmacol. 1975 Apr;53(4):539–546. doi: 10.1111/j.1476-5381.1975.tb07392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hong S. L., Levine L. Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc Natl Acad Sci U S A. 1976 May;73(5):1730–1734. doi: 10.1073/pnas.73.5.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Humes J. L., Bonney R. J., Pelus L., Dahlgren M. E., Sadowski S. J., Kuehl F. A., Jr, Davies P. Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature. 1977 Sep 8;269(5624):149–151. doi: 10.1038/269149a0. [DOI] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Mooney C., Elsbach P. Altered phospholipid metabolism in Escherichia coli accompanying killing by disrupted granulocytes. Infect Immun. 1975 Jun;11(6):1269–1277. doi: 10.1128/iai.11.6.1269-1277.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  15. Weiss J., Elsbach P. The use of a phospholipase A-less Escherichia coli mutant to establish the action of granulocyte phospholipase A on bacterial phospholipids during killing by a highly purified granulocyte fraction. Biochim Biophys Acta. 1977 Apr 1;466(1):23–33. doi: 10.1016/0005-2736(77)90205-x. [DOI] [PubMed] [Google Scholar]
  16. Weiss J., Franson R. C., Beckerdite S., Schmeidler K., Elsbach P. Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli. J Clin Invest. 1975 Jan;55(1):33–42. doi: 10.1172/JCI107915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. van den Bosch H. Phosphoglyceride metabolism. Annu Rev Biochem. 1974;43(0):243–277. doi: 10.1146/annurev.bi.43.070174.001331. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES